arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

HALOZYME THERAPEUTICS, INC.

HALO
$103.05 ▲ +17.23 (+20.08%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
67 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
74
Health
Good
Neutral
auto_awesome

Analytical Summary

HALOZYME THERAPEUTICS, INC. demonstrates solid fundamentals with strength in Profit Margin (%). However, watch Debt to Equity which shows concerning trends. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $12.2B
Dividend Yield
Revenue Growth 42.2%
Op. Margin 49.0%
ROIC 7.1%
FCF / Share $1.49
Trailing P/E 81.1x
Price / Book 55.6x
FCF Yield 1.5%
Debt / Equity 8.81
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$376.71M
↑ +42.2%
Net Income Profit after all expenses
$150.05M
↑ +27.1%
Operating Margin Operating profit as % of sales
49.0%
↑ +338.2% 89th
FCF / Share Free cash flow per share
$1.49
↑ +20.0%
Long-Term Debt Long-term obligations
$1.94B
↓ -9.6%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
90
Financial Health
47
Cash Quality
86

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters